The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin
Summary Xeroderma pigmentosum (XP) is a rare autosomal recessive photosensitive disorder, which results in multiple face, neck and head basal cell carcinomas (BCCs), squamous cell carcinomas and melanomas. A 15‐year‐old boy with XP presented with multiple facial BCCs previously treated by surgical e...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental dermatology 2003-11, Vol.28 (s1), p.33-35 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 35 |
|---|---|
| container_issue | s1 |
| container_start_page | 33 |
| container_title | Clinical and experimental dermatology |
| container_volume | 28 |
| creator | Giannotti, B. Vanzi, L. Difonzo, E. M. Pimpinelli, N. |
| description | Summary Xeroderma pigmentosum (XP) is a rare autosomal recessive photosensitive disorder, which results in multiple face, neck and head basal cell carcinomas (BCCs), squamous cell carcinomas and melanomas. A 15‐year‐old boy with XP presented with multiple facial BCCs previously treated by surgical excision. Standard BCC treatments such as surgery are not ideal for patients with several facial BCCs because of the risk of scarring, and the patient refused further surgery. As an alternative, three times weekly application of imiquimod 5% cream in combination with oral acitretin (20 mg daily) was prescribed for 4–6 weeks. No adverse events were reported during treatment and all tumours had resolved at the 6‐month follow up visit, highlighting the therapeutic potential of imiquimod 5% cream. |
| doi_str_mv | 10.1046/j.1365-2230.28.s1.11.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71368564</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>494763381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3771-6eb8b607368c59a5aa374dba1c3c0d805d1b92a459c44497d91acc578f0dfc7f3</originalsourceid><addsrcrecordid>eNpdkd1u1DAQhSMEokvhFSoLCe4SPHH8E3GFlrIFFbhgERI31sTxUi_reGsn6vYVeOo62lIkbmxp5jtz7DNFcQa0AtqIN9sKmOBlXTNa1apKUAFUh0fF4qH8uFhQRmUpWqZOimcpbSkFBpI_LU6gESAUwKL4s76yZIwWR2-HkYQN6TDhjhi7ywdG44bgMRE3ECR7HN1M3bjxihxsDL2NPpfdr1kc0uSPLSQm-M4NGQ_DPNN5dz05H3rCXxGT3TzBoSchZic0LvuPbnhePNngLtkX9_dp8f3D-Xp5UV5-XX1cvrssDZMSSmE71QkqmVCGt8gRmWz6DsEwQ3tFeQ9dW2PDW9M0TSv7FtAYLtWG9hsjN-y0eH2cu4_herJp1N6l-b842DAlLXOEiosmgy__A7dhikN-m67nKBXndYbO7qGp87bX--g8xlv9N-IMvD0CN25nb__1qZ4Xqbd63pieN6ZrpRNoAH3Qy_P3wNpZXR7VLo328KDG-FsLySTXP76s9KfVz8_rum71N3YHAcyhzQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>201318552</pqid></control><display><type>article</type><title>The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Giannotti, B. ; Vanzi, L. ; Difonzo, E. M. ; Pimpinelli, N.</creator><creatorcontrib>Giannotti, B. ; Vanzi, L. ; Difonzo, E. M. ; Pimpinelli, N.</creatorcontrib><description>Summary Xeroderma pigmentosum (XP) is a rare autosomal recessive photosensitive disorder, which results in multiple face, neck and head basal cell carcinomas (BCCs), squamous cell carcinomas and melanomas. A 15‐year‐old boy with XP presented with multiple facial BCCs previously treated by surgical excision. Standard BCC treatments such as surgery are not ideal for patients with several facial BCCs because of the risk of scarring, and the patient refused further surgery. As an alternative, three times weekly application of imiquimod 5% cream in combination with oral acitretin (20 mg daily) was prescribed for 4–6 weeks. No adverse events were reported during treatment and all tumours had resolved at the 6‐month follow up visit, highlighting the therapeutic potential of imiquimod 5% cream.</description><identifier>ISSN: 0307-6938</identifier><identifier>EISSN: 1365-2230</identifier><identifier>DOI: 10.1046/j.1365-2230.28.s1.11.x</identifier><identifier>PMID: 14616811</identifier><identifier>CODEN: CEDEDE</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing</publisher><subject>Acitretin - administration & dosage ; Administration, Oral ; Administration, Topical ; Adolescent ; Aminoquinolines - administration & dosage ; Antineoplastic Agents - administration & dosage ; Carcinoma, Basal Cell - complications ; Carcinoma, Basal Cell - drug therapy ; Drug Therapy, Combination ; Facial Neoplasms - complications ; Facial Neoplasms - drug therapy ; Humans ; Imiquimod ; Keratolytic Agents - administration & dosage ; Male ; Treatment Outcome ; Xeroderma Pigmentosum - complications</subject><ispartof>Clinical and experimental dermatology, 2003-11, Vol.28 (s1), p.33-35</ispartof><rights>Copyright Blackwell Science Ltd. Nov 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3771-6eb8b607368c59a5aa374dba1c3c0d805d1b92a459c44497d91acc578f0dfc7f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14616811$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giannotti, B.</creatorcontrib><creatorcontrib>Vanzi, L.</creatorcontrib><creatorcontrib>Difonzo, E. M.</creatorcontrib><creatorcontrib>Pimpinelli, N.</creatorcontrib><title>The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin</title><title>Clinical and experimental dermatology</title><addtitle>Clin Exp Dermatol</addtitle><description>Summary Xeroderma pigmentosum (XP) is a rare autosomal recessive photosensitive disorder, which results in multiple face, neck and head basal cell carcinomas (BCCs), squamous cell carcinomas and melanomas. A 15‐year‐old boy with XP presented with multiple facial BCCs previously treated by surgical excision. Standard BCC treatments such as surgery are not ideal for patients with several facial BCCs because of the risk of scarring, and the patient refused further surgery. As an alternative, three times weekly application of imiquimod 5% cream in combination with oral acitretin (20 mg daily) was prescribed for 4–6 weeks. No adverse events were reported during treatment and all tumours had resolved at the 6‐month follow up visit, highlighting the therapeutic potential of imiquimod 5% cream.</description><subject>Acitretin - administration & dosage</subject><subject>Administration, Oral</subject><subject>Administration, Topical</subject><subject>Adolescent</subject><subject>Aminoquinolines - administration & dosage</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Carcinoma, Basal Cell - complications</subject><subject>Carcinoma, Basal Cell - drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Facial Neoplasms - complications</subject><subject>Facial Neoplasms - drug therapy</subject><subject>Humans</subject><subject>Imiquimod</subject><subject>Keratolytic Agents - administration & dosage</subject><subject>Male</subject><subject>Treatment Outcome</subject><subject>Xeroderma Pigmentosum - complications</subject><issn>0307-6938</issn><issn>1365-2230</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkd1u1DAQhSMEokvhFSoLCe4SPHH8E3GFlrIFFbhgERI31sTxUi_reGsn6vYVeOo62lIkbmxp5jtz7DNFcQa0AtqIN9sKmOBlXTNa1apKUAFUh0fF4qH8uFhQRmUpWqZOimcpbSkFBpI_LU6gESAUwKL4s76yZIwWR2-HkYQN6TDhjhi7ywdG44bgMRE3ECR7HN1M3bjxihxsDL2NPpfdr1kc0uSPLSQm-M4NGQ_DPNN5dz05H3rCXxGT3TzBoSchZic0LvuPbnhePNngLtkX9_dp8f3D-Xp5UV5-XX1cvrssDZMSSmE71QkqmVCGt8gRmWz6DsEwQ3tFeQ9dW2PDW9M0TSv7FtAYLtWG9hsjN-y0eH2cu4_herJp1N6l-b842DAlLXOEiosmgy__A7dhikN-m67nKBXndYbO7qGp87bX--g8xlv9N-IMvD0CN25nb__1qZ4Xqbd63pieN6ZrpRNoAH3Qy_P3wNpZXR7VLo328KDG-FsLySTXP76s9KfVz8_rum71N3YHAcyhzQ</recordid><startdate>200311</startdate><enddate>200311</enddate><creator>Giannotti, B.</creator><creator>Vanzi, L.</creator><creator>Difonzo, E. M.</creator><creator>Pimpinelli, N.</creator><general>Blackwell Publishing</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>200311</creationdate><title>The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin</title><author>Giannotti, B. ; Vanzi, L. ; Difonzo, E. M. ; Pimpinelli, N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3771-6eb8b607368c59a5aa374dba1c3c0d805d1b92a459c44497d91acc578f0dfc7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Acitretin - administration & dosage</topic><topic>Administration, Oral</topic><topic>Administration, Topical</topic><topic>Adolescent</topic><topic>Aminoquinolines - administration & dosage</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Carcinoma, Basal Cell - complications</topic><topic>Carcinoma, Basal Cell - drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Facial Neoplasms - complications</topic><topic>Facial Neoplasms - drug therapy</topic><topic>Humans</topic><topic>Imiquimod</topic><topic>Keratolytic Agents - administration & dosage</topic><topic>Male</topic><topic>Treatment Outcome</topic><topic>Xeroderma Pigmentosum - complications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giannotti, B.</creatorcontrib><creatorcontrib>Vanzi, L.</creatorcontrib><creatorcontrib>Difonzo, E. M.</creatorcontrib><creatorcontrib>Pimpinelli, N.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giannotti, B.</au><au>Vanzi, L.</au><au>Difonzo, E. M.</au><au>Pimpinelli, N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin</atitle><jtitle>Clinical and experimental dermatology</jtitle><addtitle>Clin Exp Dermatol</addtitle><date>2003-11</date><risdate>2003</risdate><volume>28</volume><issue>s1</issue><spage>33</spage><epage>35</epage><pages>33-35</pages><issn>0307-6938</issn><eissn>1365-2230</eissn><coden>CEDEDE</coden><abstract>Summary Xeroderma pigmentosum (XP) is a rare autosomal recessive photosensitive disorder, which results in multiple face, neck and head basal cell carcinomas (BCCs), squamous cell carcinomas and melanomas. A 15‐year‐old boy with XP presented with multiple facial BCCs previously treated by surgical excision. Standard BCC treatments such as surgery are not ideal for patients with several facial BCCs because of the risk of scarring, and the patient refused further surgery. As an alternative, three times weekly application of imiquimod 5% cream in combination with oral acitretin (20 mg daily) was prescribed for 4–6 weeks. No adverse events were reported during treatment and all tumours had resolved at the 6‐month follow up visit, highlighting the therapeutic potential of imiquimod 5% cream.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing</pub><pmid>14616811</pmid><doi>10.1046/j.1365-2230.28.s1.11.x</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0307-6938 |
| ispartof | Clinical and experimental dermatology, 2003-11, Vol.28 (s1), p.33-35 |
| issn | 0307-6938 1365-2230 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71368564 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Acitretin - administration & dosage Administration, Oral Administration, Topical Adolescent Aminoquinolines - administration & dosage Antineoplastic Agents - administration & dosage Carcinoma, Basal Cell - complications Carcinoma, Basal Cell - drug therapy Drug Therapy, Combination Facial Neoplasms - complications Facial Neoplasms - drug therapy Humans Imiquimod Keratolytic Agents - administration & dosage Male Treatment Outcome Xeroderma Pigmentosum - complications |
| title | The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T15%3A03%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20treatment%20of%20basal%20cell%20carcinomas%20in%20a%20patient%20with%20xeroderma%20pigmentosum%20with%20a%20combination%20of%20imiquimod%205%25%20cream%20and%20oral%20acitretin&rft.jtitle=Clinical%20and%20experimental%20dermatology&rft.au=Giannotti,%20B.&rft.date=2003-11&rft.volume=28&rft.issue=s1&rft.spage=33&rft.epage=35&rft.pages=33-35&rft.issn=0307-6938&rft.eissn=1365-2230&rft.coden=CEDEDE&rft_id=info:doi/10.1046/j.1365-2230.28.s1.11.x&rft_dat=%3Cproquest_pubme%3E494763381%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=201318552&rft_id=info:pmid/14616811&rfr_iscdi=true |